Shigeto Ueda1, Nobuko Yoshizawa2, Takashi Shigekawa3, Hideki Takeuchi3, Hiroyuki Ogura4, Akihiko Osaki3, Toshiaki Saeki3, Yukio Ueda5, Tomohiko Yamane6, Ichiei Kuji6, Harumi Sakahara2. 1. Department of Breast Oncology, International Medical Center, Saitama Medical University, Yamane, Hidaka, Japan syueda@saitama-med.ac.jp. 2. Department of Diagnostic Radiology and Nuclear Medicine, Hamamatsu University, School of Medicine, Handayama, Hamamatsu, Japan. 3. Department of Breast Oncology, International Medical Center, Saitama Medical University, Yamane, Hidaka, Japan. 4. Department of Breast Surgery, Hamamatsu University, School of Medicine, Handayama, Hamamatsu, Japan. 5. Central Research Laboratory, Hamamatsu Photonics K.K., Hamakitaku, Hamamatsu, Japan; and. 6. Department of Nuclear Medicine, International Medical Center, Saitama Medical University, Yamane, Hidaka, Japan.
Abstract
UNLABELLED: Diffuse optical spectroscopic imaging (DOSI) is used as an indicator of tumor blood volume quantified by tissue hemoglobin concentrations. We aimed to determine whether early changes in tumor total hemoglobin (tHb) concentration can predict a pathologic complete response (pCR) to neoadjuvant chemotherapy in patients with operable breast cancer, and we compared the predictive value of pCR between DOSI and (18)F-FDG PET combined with CT. METHODS: Of the 100 patients enrolled, 84 patients were prospectively evaluated for primary objective analysis. Sixty-four of the patients underwent both sequential DOSI scans at baseline after their first and second chemotherapy courses and (18)F-FDG PET/CT at baseline and after their second chemotherapy course. The mean tHb (tHbmean) concentration and SUVmax of the lesion were measured using DOSI and (18)F-FDG PET/CT, respectively, and the percentage change in tHbmean (∆tHbmean) and change in SUVmax (∆SUVmax) were calculated. We compared the diagnostic performances of DOSI and (18)F-FDG PET/CT for predicting pCR via the analysis of the receiver-operating-characteristic curves. RESULTS: pCR was achieved in 16 patients, and neoadjuvant chemotherapy caused a significant reduction of ∆tHbmean in pCR compared with non-pCR after the 2 chemotherapy courses. When the tentative ∆tHbmean cutoff values after the first and second courses were used, the ability to predict pCR was as follows: 81.2% sensitivity/47.0% specificity and 93.7% sensitivity/47.7% specificity, respectively. Comparison of the diagnostic performances of DOSI and (18)F-FDG PET/CT revealed areas under the curve of 0.69 and 0.75 of ∆tHbmean after the first and second courses, respectively, which were lower than those of ∆SUVmax (0.90). CONCLUSION: DOSI predicted pCR in patients with breast cancer with moderate accuracy. The diagnostic performance of DOSI was inferior to that of the early metabolic response as monitored by (18)F-FDG PET/CT.
UNLABELLED: Diffuse optical spectroscopic imaging (DOSI) is used as an indicator of tumor blood volume quantified by tissue hemoglobin concentrations. We aimed to determine whether early changes in tumor total hemoglobin (tHb) concentration can predict a pathologic complete response (pCR) to neoadjuvant chemotherapy in patients with operable breast cancer, and we compared the predictive value of pCR between DOSI and (18)F-FDG PET combined with CT. METHODS: Of the 100 patients enrolled, 84 patients were prospectively evaluated for primary objective analysis. Sixty-four of the patients underwent both sequential DOSI scans at baseline after their first and second chemotherapy courses and (18)F-FDG PET/CT at baseline and after their second chemotherapy course. The mean tHb (tHbmean) concentration and SUVmax of the lesion were measured using DOSI and (18)F-FDG PET/CT, respectively, and the percentage change in tHbmean (∆tHbmean) and change in SUVmax (∆SUVmax) were calculated. We compared the diagnostic performances of DOSI and (18)F-FDG PET/CT for predicting pCR via the analysis of the receiver-operating-characteristic curves. RESULTS: pCR was achieved in 16 patients, and neoadjuvant chemotherapy caused a significant reduction of ∆tHbmean in pCR compared with non-pCR after the 2 chemotherapy courses. When the tentative ∆tHbmean cutoff values after the first and second courses were used, the ability to predict pCR was as follows: 81.2% sensitivity/47.0% specificity and 93.7% sensitivity/47.7% specificity, respectively. Comparison of the diagnostic performances of DOSI and (18)F-FDG PET/CT revealed areas under the curve of 0.69 and 0.75 of ∆tHbmean after the first and second courses, respectively, which were lower than those of ∆SUVmax (0.90). CONCLUSION: DOSI predicted pCR in patients with breast cancer with moderate accuracy. The diagnostic performance of DOSI was inferior to that of the early metabolic response as monitored by (18)F-FDG PET/CT.
Authors: Mirella L Altoe; Kevin Kalinsky; Alessandro Marone; Hyun K Kim; Hua Guo; Hanina Hibshoosh; Mariella Tejada; Katherine D Crew; Melissa K Accordino; Meghna S Trivedi; Dawn L Hershman; Andreas H Hielscher Journal: Clin Cancer Res Date: 2021-01-15 Impact factor: 12.531
Authors: Emerson A Lim; Jacqueline E Gunther; Hyun K Kim; Molly Flexman; Hanina Hibshoosh; Katherine Crew; Bret Taback; Jessica Campbell; Kevin Kalinsky; Andreas Hielscher; Dawn L Hershman Journal: Breast Cancer Res Treat Date: 2017-02-11 Impact factor: 4.624
Authors: Yong Hong Liu; Ling Bo Xue; Yan Fang Yang; Tian Jiao Zhao; Yang Bai; Bu Yong Zhang; Jie Li Journal: Medicine (Baltimore) Date: 2018-10 Impact factor: 1.817
Authors: Quing Zhu; Susan Tannenbaum; Scott H Kurtzman; Patricia DeFusco; Andrew Ricci; Hamed Vavadi; Feifei Zhou; Chen Xu; Alex Merkulov; Poornima Hegde; Mark Kane; Liqun Wang; Kert Sabbath Journal: Breast Cancer Res Date: 2018-06-14 Impact factor: 6.466